J Gynecol Oncol.  2022 Mar;33(2):e43. 10.3802/jgo.2022.33.e43.

Major clinical research advances in gynecologic cancer in 2021

• Park JY
• Lee JY
• Lee YY
• Shim SH
• Suh DH
• Kim JW

• KMID: 2536891
• DOI: http://doi.org/10.3802/jgo.2022.33.e43

Abstract

In the 2021 series, we not only summarized the major clinical research advances in gynecologic oncology but also added discussions to every part, based on communications at the conference. A review of cervical cancer included adjuvant treatments such as radiation and chemoradiation (concurrent or sequential) after radical hysterectomy in early cervical cancer, and immune checkpoint inhibitors in advanced, recurrent, and metastatic disease. Ovarian cancer research included studies of secondary cytoreductive surgery in platinum-sensitive recurrent ovarian cancer, and various trials of immune checkpoint inhibitors with or without vascular endothelial growth factor inhibitors and conventional chemotherapy. The rechallenge of poly (ADP-ribose) polymerase inhibitor maintenance in heavily pretreated ovarian cancer were also addressed. For uterine corpus cancer, dostarlimab (anti-programmed cell death protein 1 antibody) alone, or a tyrosine kinase inhibitor in combination with pembrolizumab for advanced, metastatic, or recurrent endometrial cancer were reviewed. The survival differences between the intensive and minimalist follow-up protocols were also described. In this review, we compared salpingectomy with delayed oophorectomy and salpingo-oophorectomy in terms of quality of life in BRCA 1 and 2 pathogenic variant carriers.

Keyword

Immunotherapy; Molecular Targeted Therapy; Poly(ADP-Ribose) Polymerase; Adjuvant Chemotherapy; Adjuvant Radiotherapy; Cytoreduction Surgical Procedures; Prevention